Risk-Adjusted NPV Calculator
Model the probability-weighted value of a drug pipeline asset. Set market assumptions, adjust stage probabilities and financial parameters, and see results update in real-time.
💻
Desktop Required
The rNPV calculator is optimised for desktop use. Please open this page on a larger screen to access the full tool.
rNPV Dashboard
Oncology · Pre-clinical
Asset Details
Market Assumptions
Financial Parameters
Revenue Profile
Stage Parameters
| Stage | Cost ($M) | Duration (yrs) | P(Advance) % |
|---|---|---|---|
| Pre-clinical | |||
| Phase I | |||
| Phase II | |||
| Phase III | |||
| Regulatory |
Calculated rNPV
$44.7M
Adjusted Valuation (Post Risk Modifiers)
$38.0M
Phase-by-Phase Build-up
✓rNPV includes risk, WACC, and market modifiers
P(Market Launch)
2.3%
Exp. Dev Cost
$56.8M
Peak Revenue
$7.5B
Net Margin
35.5%
Detailed Analysis
Stage Contributions
Cash Flow Timeline
Sensitivity Analysis
rNPV at ±20% peak revenue and ±2% WACC
| Revenue | 10% WACC | 12% WACC | 14% WACC |
|---|---|---|---|
| 80% | $50.1M | $28.3M | $13.2M |
| 100% | $72.6M | $44.7M | $25.3M |
| 120% | $95.0M | $61.2M | $37.4M |
How It Works
Everything you need to know about rNPV methodology and using this calculator.
Risk-adjusted Net Present Value (rNPV) is the pharmaceutical industry's standard method for valuing pre-revenue drug development assets. Unlike a traditional DCF that uses a single discount rate to capture all risk, rNPV explicitly applies stage-specific probabilities of success to each cash flow.
The core formula: rNPV = Σ (CFₜ × P(success)ₜ) / (1 + WACC)ₜ
Where P(success) is the cumulative probability of reaching each stage, compounding from the current development phase through market launch. A drug in Phase III is worth more than the same molecule in preclinical — not because its commercial potential changed, but because the probability of reaching the market is dramatically higher.
- Select your therapeutic area — this automatically loads industry-standard transition probabilities from BIO/Informa clinical trial data.
- Set the current development stage — the calculator only models costs and probabilities from this stage forward.
- Enter market assumptions — addressable patients, expected market share, and pricing. These drive the revenue forecast.
- Adjust financial parameters — WACC, tax rate, COGS, SG&A, and royalty rate determine your net cash flow per dollar of revenue.
- Set the revenue profile — patent life determines how long you earn exclusivity revenue before generic erosion.
- Fine-tune stage parameters — override the default per-stage cost, duration, and probability of advancement if you have asset-specific data.
- Results update in real-time. Use the sensitivity table to stress-test your assumptions.
Market Assumptions
Addressable Patients: Total eligible patient population in millions. This isn't the total disease prevalence — it's the subset who would be candidates for your therapy based on indication, line of therapy, and geography.
Peak Market Share: Maximum market penetration at steady state. For first-in-class drugs, 30-50% is aggressive. For crowded markets, 10-20% is more realistic.
Price per Treatment: Annual or per-course price in dollars. Research comparable approved drugs in your therapeutic area.
Financial Parameters
WACC: Weighted Average Cost of Capital. Biotech typically ranges 10-15%. Pre-revenue companies often use 12-15%; large pharma uses 8-10%.
COGS: Cost of goods sold as a percentage of revenue. Small molecules: 15-25%. Biologics: 25-35%. Gene therapies: 30-50%.
SG&A: Selling, general, and administrative expenses. Includes sales force, marketing, and corporate overhead. Typically 15-25% of revenue.
Royalty Rate: Licensing or IP royalty obligations owed to third parties. 0% if fully owned; 3-10% if in-licensed.
Revenue Profile
Patent Life: Years of market exclusivity from launch. Standard composition-of-matter patents provide ~12-15 years from filing, minus development time.
Generic Erosion: Annual revenue decline after loss of exclusivity. Branded drugs typically lose 60-90% of volume within 2-3 years of generic entry.
Market Risk Adjustment: Additional discount for competitive dynamics, IP risk, manufacturing feasibility, or regulatory pathway uncertainty not captured by stage probabilities.
rNPV: The probability-weighted, time-discounted value of all expected cash flows. Positive rNPV means the asset is expected to create value; negative means expected costs outweigh risk-adjusted revenue.
Adjusted Valuation: rNPV after applying the Market Risk Adjustment. This is your "real-world" estimate that accounts for factors beyond clinical probability — competition, IP, and execution risk.
Phase Build-up Chart: Shows how the asset's value increases as it progresses through development stages. Each bar represents the rNPV if the drug were currently at that stage. The difference between bars is the "value inflection" — the value created by successfully passing each clinical milestone.
Stage Contributions: Waterfall showing each development stage's cost impact and the revenue contribution. Costs are negative (red), revenue is positive (green).
Sensitivity Analysis: 3×3 grid showing how rNPV changes with ±20% revenue and ±2% WACC. The base case is highlighted. Use this to understand which assumptions your valuation is most sensitive to.
Methodology & Data Sources
Default parameters, transition probabilities, and the underlying literature this model draws from. All assumptions are editable in the calculator above.
Stage-Transition Probabilities by Therapeutic Area
P(advance) for each clinical phase. Sourced from BIO/Informa 2011–2020 dataset[2] and prior BIO/BioMedTracker reports[1,5]. LoA = likelihood of approval from pre-clinical.
| Therapeutic Area | Pre→P1 | P1→P2 | P2→P3 | P3→Reg | Reg→Mkt | LoA |
|---|---|---|---|---|---|---|
| Oncology | 50% | 52% | 29% | 36% | 85% | 2.3% |
| Rare Disease | 50% | 64% | 38% | 63% | 90% | 6.9% |
| Infectious Disease | 50% | 59% | 33% | 58% | 85% | 4.8% |
| CNS (Central Nervous System) | 50% | 51% | 29% | 50% | 85% | 3.1% |
| Cardiovascular | 50% | 59% | 24% | 52% | 85% | 3.1% |
| Autoimmune | 50% | 55% | 32% | 57% | 85% | 4.3% |
| Gene Therapy | 45% | 58% | 35% | 60% | 88% | 4.8% |
Default Development Cost & Duration Assumptions
Median estimates by phase. Costs in 2020 USD. Sources: DiMasi et al. 2016[3] and Wouters et al. 2020[4]. Actual costs vary substantially by therapeutic area, trial design, and geography.
| Stage | Default Cost | Duration | Notes |
|---|---|---|---|
| Pre-clinical | $15M | 2 yrs | In vitro/in vivo; excludes target discovery |
| Phase I | $25M | 1.5 yrs | Safety, PK/PD; typically 20–100 subjects |
| Phase II | $60M | 2.5 yrs | Proof of concept; 100–300 subjects |
| Phase III | $180M | 3 yrs | Pivotal efficacy; 1,000–3,000 subjects |
| Regulatory Review | $5M | 1.5 yrs | NDA/BLA preparation and FDA review fee |
Financial Parameter Defaults & Typical Ranges
Default values are starting points only. Adjust to reflect asset-specific commercial and financial characteristics.
| Parameter | Default | Typical Range | Notes |
|---|---|---|---|
| WACC | 12% | 8–15% | Higher for early-stage; large pharma typically 8–10% |
| Corporate Tax Rate | 21% | 15–28% | US federal statutory rate (TCJA 2017) |
| COGS | 30% | 15–50% | Small molecules 15–25%; biologics/gene therapies 30–50% |
| SG&A | 20% | 15–30% | Includes sales force, marketing, and corporate overhead |
| Royalty Rate | 5% | 0–15% | 0% if fully owned; 3–10% for in-licensed IP |
| Patent Life | 12 yrs | 8–20 yrs | From launch; composition-of-matter patents typically 10–15 yrs post-launch |
| Generic Erosion Rate | 60%/yr | 20–90%/yr | US market: branded drugs typically lose 60–90% of volume within 2–3 years of generic entry |
| Years to Peak Sales | 6 yrs | 3–10 yrs | Time from launch to peak revenue; specialty drugs often reach peak faster |
| Market Risk Adjustment | 15% | 0–40% | Additional discount for competitive, IP, and execution risks not captured by stage probabilities |
Revenue Model Structure
1 — Ramp Phase
Linear ramp from zero to peak gross revenue over yearsToPeak. Reflects adoption curve as prescribers gain clinical experience and payer coverage expands.
2 — Exclusivity Plateau
Peak revenue maintained through patent expiry. Net cash flow = gross × (1 − COGS − SG&A − royalty) × (1 − tax). Discounted at WACC.
3 — Generic Erosion Tail
After loss of exclusivity, revenue decays annually by genericErosionRate. Model runs 3 post-LOE years before truncating.
rNPV = Σ [CFₜ × P(success)ₜ] / (1 + WACC)ₜ — where P(success)ₜ compounds stage probabilities from the selected current stage through market launch
Peak gross revenue = addressablePatients × peakMarketShare × pricePerTreatment. This model assumes a single indication and does not include portfolio effects, real options, or Monte Carlo simulation.
References
- [1]Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nature Biotechnology. 2014. 32(1):40–51. https://doi.org/10.1038/nbt.2786
- [2]BIO / QLS Advisors / Informa Pharma Intelligence. Clinical Development Success Rates and Contributing Factors 2011–2020. 2021. Industry report. Full report ↗
- [3]DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics. 2016. 47:20–33. https://doi.org/10.1016/j.jhealeco.2016.01.012
- [4]Wouters OJ, McKee M, Luyten J. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009–2018. JAMA. 2020. 323(9):844–853. https://doi.org/10.1001/jama.2020.1166
- [5]Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019. 20(2):273–286. https://doi.org/10.1093/biostatistics/kxx069
If this tool saved you time, consider buying me a coffee.☺️
☕ Buy me a coffee